A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
405actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-04 | actual | When the study began enrolling |
| Primary completion | 2026-01-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Influenza A
Interventions
- Biological: AZD4117
- Biological: AZD5315
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with immediate unsolicited adverse events (AE)
measured Within 30 minutes after dosing
Percentage of participants with injection site and systemic solicited adverse reactions (AR)
measured Through 7 days after dosing
Percentage of participants with unsolicited AE
measured Through 28 days after the last dose
Percentage of participants with serious adverse events (SAE)
measured Through 12 months after the last dose
Percentage of participants with medically attended adverse events (MAAE)
measured Through 12 months after the last dose
Percentage of participants with adverse events of special interest (AESI)
measured Through 12 months after the last dose
Proportion of participants achieving ≥ 1:40 HAI titer post-IMP administration
measured Day 58
Proportion of participants achieving seroconversion post-IMP administration
measured Day 58
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed